Frequently Asked Questions

Yes. TULSA-PRO^TM is FDA-approved and recognized by the American Urological Association. It has been validated through rigorous clinical trials and is trusted by leading medical institutions worldwide.

Most patients return to normal activity within days and feel fully recovered within two weeks. The minimally invasive nature of TULSA-PRO^TM means significantly shorter recovery times compared to traditional surgical approaches.

Yes, temporarily. Most patients describe it as manageable and short-term. The catheter is typically removed within a few days to weeks, and patients can resume normal activities shortly after.

Pre- and post-procedure care is often covered. The procedure itself is self-pay. We recommend contacting your insurance provider to understand your specific coverage and benefits.

Patients consistently tell us the outcome—health, confidence, peace of mind—was priceless, and the investment in their health and quality of life was invaluable.

Candidates are typically men with localized prostate cancer who want to preserve sexual function and bladder control. Dr. Hong performs a detailed MRI review to confirm candidacy for each patient.

TULSA-PRO^TM demonstrates excellent outcomes: 92% pad-free continence, 87% potency preserved, and 79%+ cancer control at 5 years. These rates are significantly better than traditional treatments in many cases, and may even be higher for your situation.

TULSA-PRO^TM is the only MRI-guided, whole-gland-enabled ablation therapy. Other minimally-invasive treatments are focal only or do not utilize MRI-precision. TULSA-PRO^TM combines precision with minimal invasiveness, offering superior outcomes for sexual function and continence compared to surgery or radiation.